目的 探讨应用双歧杆菌三联活菌胶囊联合血必净注射液治疗术后早期炎性肠梗阻的临床效果。方法 选取宜昌市第二人民医院2015年3月—2017年3月收治的术后早期炎性肠梗阻患者96例，随机分为对照组（48例）和治疗组（48例）。对照组静脉滴注血必净注射液，50 mL加入生理盐水100 mL，2次/d。治疗组在对照组基础上口服双歧杆菌三联活菌胶囊，2粒/次，2次/d。两组均连续治疗1周。观察两组患者临床疗效，比较治疗前后两组患者胃肠减压量、症状改善时间、炎性因子、淋巴细胞和PCT水平及氧化应激和肠黏膜功能指标变化。结果 治疗后，对照组和治疗组的临床有效率分别为85.42%和95.83%，两组比较差异具有统计学意义（P<0.05）。治疗后，治疗组胃肠减压量明显低于对照组（P<0.01），且症状改善时间均明显短于对照组（P<0.01）。治疗后，两组腹腔引流液中C反应蛋白（CRP）、肿瘤坏死因子（TNF）-α、白细胞介素（IL）-6和IL-1β水平显著下降（P<0.01）；且治疗组比对照组降低更显著（P<0.01）。治疗后，两组患者外周血CD⁴⁺和CD⁴⁺/CD⁸⁺比值均显著增加，外周血CD¹⁹⁺值和血清降钙素原（PCT）水平显著降低，同组比较差异具有统计学意义（P<0.01）；且治疗组患者淋巴细胞和PCT水平比对照组改善更明显（P<0.01）。治疗后，两组患者血清超氧化物歧化酶（SOD）水平显著升高，血清丙二醛（MDA）、二胺氧化酶（DAO）、D-乳酸水平显著降低，同组比较差异具有统计学意义（P<0.01）；且治疗组上述指标比对照组改善更显著（P<0.01）。结论 双歧杆菌三联活菌胶囊联合血必净注射液治疗术后早期炎性肠梗阻可迅速缓解患者腹痛、腹胀等症状，有效减轻肠壁粘膜炎症，改善肠黏膜功能。

Objective To investigate the clinical effect of Bifidobacterium Triple Live Capsules combined with Xuebijing Injection in treatment of early postoperative inflammatory ileus. Methods Patients (96 cases) with early postoperative inflammatory ileus in the Second People's Hospital of Yichang from March 2015 to March 2017 were randomly divided into control (48 cases) and treatment (48 cases). Patients in the control group were iv administered with Xuebijing Injection, 50 mL added into normal saline 100 mL, twice daily. Patients in the treatment group were po administered with Bifidobacterium Triple Live Capsules on the basis of the control group, 2 grains/time, twice daily. Patients in two groups were treated for 1 week. After treatment, the clinical efficacy was evaluated, and the changes of the gastrointestinal decompression, the symptom improvement time, the inflammatory factors, the lymphocytes and PCT levels, the oxidative stress and intestinal mucosal function in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 85.42% and 95.83% respectively, and there were differences between two groups (P < 0.05). After treatment, the gastrointestinal decompression in the treatment group was significantly lower than that in the control group (P < 0.01), the symptom improvement time the treatment group was significantly shorter than that in the control group (P < 0.01). After treatment, the CRP, TNF-α, IL-6 and IL-1β levels in two groups were significantly decreased (P < 0.01). And the inflammatory factors levels in the treatment group after treatment were significantly lower than those in the control group (P < 0.01). After treatment, the CD⁴⁺ and CD⁴⁺/CD⁸⁺ of peripheral blood in two groups were significantly increased, but the CD¹⁹⁺ of peripheral blood and PCT levels were significantly decreased, and there were differences in the same group (P < 0.01). And the lymphocytes and PCT levels in the treatment group after treatment were significantly better than those in the control group, with significant difference between two groups (P < 0.01). After treatment, the SOD levels in two groups were significantly increased, but the MDA, DAO and D-lactate levels were significantly decreased, and the difference was statistically significant in the same group (P < 0.01). And these indicators in the treatment group after treatment were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Bifidobacterium Triple Live Capsules combined with Xuebijing Injection in treatment of early postoperative inflammatory ileus can quickly alleviate the symptoms of abdominal pain and abdominal distension, and effectively reduce the intestinal mucosal inflammation, and improve the intestinal mucosal function.